The company will conduct a trial aimed at transplanting OPCs to the site of a spinal cord injury and examining whether it could help restore some function to the patient.
Asterias Biotherapeutics is a biotechnology company focused on the emerging field of regenerative medicine.
More Articles on Spine:
Hospital for Special Surgery Names Dr. Todd Albert Surgeon-in-Chief
Costs for SI Joint Disruption, Sacroiliitis About $270M Over 5 Years
The Robotic Difference: How New Technology Could Impact Spine
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
